Ecdysoneless在胃癌组织中的表达及其意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (884 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To probe the ecdysoneless (ECD) expression and its correlation with clinical variables, such as clinical pathologic factors and prognosis in gastric cancer. Methods: ECD mRNA expression level in gastric cancer samples and matched normal gastric tissue from 56 patients was detected using Real-time PCR method. Immunohistochemical method was adopted to deteced the protein expression level of ECD in gastric cancer tiusse which with 5 years follow up. Results: ECD expression was up-regulated in gastric cancer tiusse compared with matched normal gastric tissue. Positive ECD immunoreactivity was seen in 54.0% of gastric cancer specimens, which was correlated with Lauren typing, lymph node metastasis, vessel invasion, distant metastasis, and TNM stage (P<0.05). Compared with ECD negative patients, ECD positive patients had significantly shorter survival times (35.8±1.9 month vs 45.2±1.9 month, P<0.01) and short survival rate (24.1% vs 50.0%, P<0.01). Multiariable COX regression analysis indicated that Lauren typing and TNM stage could serve as a dependent prognsis factor of gastric cancer (P<0.01), except ECD expression (P=0.212). Conclusion: ECD expression is increased in gastric cancer tissue. The ECD expression correlates with Lauren typing, lymph node metastasis, vessel invasion, distant metastasis, and TNM stage and poor survival rate in gastric cancer.

Key words： stomach neoplasms ecdysoneless prognosis

Received: 23 April 2013

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jin1
	LIU Suxia1
	WANG Qian2

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I2/117

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.

[2] 周宏众, 韩少良, 余作黔, 等. p73和COX-2在胃腺癌的表达及其预后意义[J]. 温州医学院学报, 2008, 38(6): 541-543.

[3] Zhao X, Mirza S, Alshareeda A, et al. Overexpression of aovel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients[J]. Breast Cancer Res Treat, 2012, 134(1):171-180.

[4] Dey P, Rachagani S, Chakraborty S, et al. Overexpression of ecdysoneless in pancreatic cancer and its role in onco-genesis by regulating glycolysis[J]. Clin Cancer Res, 2012,18(22): 6188-6198.

[5] Garen A, Kauvar L, Lepesant JA. Roles of ecdysone in Droso-phila development[J]. Proc Natl Acad Sci USA,1977, 74 (11): 5099-5103.

[6] Gaziova I, Bonnette PC, Henrich VC, et al. Cell autono-mous roles of the ecdysoneless gene in drosophila development and oogenesis[J]. Development, 2004, 131(11): 2715-2725.

[7] Sato T, Jigami Y, Suzuki T, et al. A human gene, hSGT1, can substitute for GCR2, which encodes a general regulatory factor of glycolytic gene expression in saccharomyces cerevisiae [J]. Mol Gen Genet, 1999, 260(6): 535-540.

[8] Kainou T, Shinzato T, Sasaki K, et al. Spsgt1, a new essen-tial gene of schizosaccharomyces pombe, is involved in car-bohydrate metabolism[J]. Yeast, 2006, 23(1): 35-53.

[9] Kim JH, Gurumurthy CB, Naramura M, et al. Role of mam-malian ecdysoneless in cell cycle regulation[J]. J Biol Chem,2009, 284(39): 26402-26410.

[10] Zhang Y, Chen J, Gurumurthy CB, et al. The human orthologue of drosophila ecdysoneless protein interacts with p53 and regulates its function[J]. Cancer Res, 2006, 66(14):7167-7175.

[11] Dey P, Rachagani S, Chakraborty S, et al. Overexpression of ecdysoneless in pancreatic cancer and its role in onco-genesis by regulating glycolysis[J]. Clin Cancer Res, 2012,18(22): 6188-6198.

[12] Zhao X, Mirza S, Alshareeda A, et al. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu overexpressing breast cancer patients[J]. Breast Cancer Res Treat, 2012, 134(1):171-180.